Novadaq Technologies Inc (NASDAQ:NVDQ) (TSE:NDQ)‘s stock had its “hold” rating reaffirmed by stock analysts at Northland Securities in a research note issued on Monday. They presently have a $11.75 target price on the medical research company’s stock. Northland Securities’ target price indicates a potential upside of 95.83% from the stock’s current price.

A number of other research firms also recently commented on NVDQ. Zacks Investment Research downgraded Novadaq Technologies from a “hold” rating to a “strong sell” rating in a report on Saturday, March 4th. Scotiabank reaffirmed an “outperform” rating and set a $18.00 target price on shares of Novadaq Technologies in a report on Wednesday, April 26th. Feltl & Co. downgraded Novadaq Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, March 1st. Royal Bank Of Canada set a $12.00 target price on Novadaq Technologies and gave the stock a “buy” rating in a report on Wednesday, March 1st. Finally, Stifel Nicolaus reduced their target price on Novadaq Technologies from $16.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, March 1st. Seven equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Novadaq Technologies currently has a consensus rating of “Hold” and an average target price of $11.85.

Analyst Recommendations for Novadaq Technologies (NASDAQ:NVDQ)

Novadaq Technologies (NASDAQ:NVDQ) traded up 95.00% during midday trading on Monday, reaching $11.70. The company had a trading volume of 23,787,867 shares. Novadaq Technologies has a 12 month low of $5.84 and a 12 month high of $12.74. The firm’s market capitalization is $676.28 million. The firm’s 50-day moving average price is $7.04 and its 200 day moving average price is $7.19.

Novadaq Technologies (NASDAQ:NVDQ) (TSE:NDQ) last issued its quarterly earnings data on Wednesday, May 3rd. The medical research company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by $0.03. Novadaq Technologies had a negative net margin of 71.97% and a negative return on equity of 49.93%. The business had revenue of $21.08 million for the quarter, compared to analyst estimates of $20.12 million. Equities analysts anticipate that Novadaq Technologies will post ($0.80) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Novadaq Technologies Inc (NVDQ) Stock Rating Reaffirmed by Northland Securities” was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/06/19/novadaq-technologies-inc-nvdq-receives-hold-rating-from-northland-securities.html.

Several hedge funds have recently made changes to their positions in NVDQ. Quantitative Systematic Strategies LLC bought a new stake in shares of Novadaq Technologies during the first quarter valued at about $169,000. Granite Investment Partners LLC increased its stake in shares of Novadaq Technologies by 164.0% in the first quarter. Granite Investment Partners LLC now owns 462,676 shares of the medical research company’s stock valued at $3,605,000 after buying an additional 287,392 shares during the period. Two Sigma Investments LP increased its stake in shares of Novadaq Technologies by 46.0% in the fourth quarter. Two Sigma Investments LP now owns 78,244 shares of the medical research company’s stock valued at $555,000 after buying an additional 24,652 shares during the period. OLD National Bancorp IN increased its stake in shares of Novadaq Technologies by 22.3% in the first quarter. OLD National Bancorp IN now owns 62,266 shares of the medical research company’s stock valued at $485,000 after buying an additional 11,360 shares during the period. Finally, US Bancorp DE increased its stake in shares of Novadaq Technologies by 0.8% in the first quarter. US Bancorp DE now owns 46,899 shares of the medical research company’s stock valued at $365,000 after buying an additional 362 shares during the period. 88.25% of the stock is currently owned by institutional investors and hedge funds.

About Novadaq Technologies

NOVADAQ Technologies Inc is a medical device company. The Company primarily develops, manufactures and markets real-time fluorescence imaging products that are designed for use by surgeons in the operating room and other clinical settings where open and minimally invasive surgery or interventional procedures are performed.

Receive News & Ratings for Novadaq Technologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novadaq Technologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.